

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,216-KK6)

| | | |
|---|---|------------------------|
| In application of: |) | |
| |) | |
| Roninson <i>et al.</i> |) | Before the Examiner: |
| |) | |
| Serial No. 10/520,142 |) | |
| |) | Group Art Unit: |
| International Filing Date: 27 June 2003 |) | |
| |) | |
| For: Reagents and Methods for |) | Confirmation No.: 5577 |
| Identifying and Modulating |) | |
| Expression of Tumor Senescence |) | |
| Genes |) | |

TRANSMITTAL LETTER

Mail Stop Missing Parts
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

In regard to the above-identified application:


1. We are transmitting herewith the attached
 - a. Response to the Notice to Comply mailed February 16, 2006
 - b. Copy of Notice to Comply
 - c. Request for Extension of Time
 - d. Sequence Listing (Computer Readable Form and Paper Copy)
 - e. Verified Statement under 37 CFR 1.821(f)
 - f. Return Postcard
2. With respect to additional fees:

A check for \$225.00 is enclosed.

Please charge any underpayment or credit any overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
3. CERTIFICATE UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and this paper, as described in paragraph 1 herein above, are being deposited with the United States Postal Service, as Express Mail, in an envelope addressed to: Assistant Commissioner of Patents, Alexandria, VA 22313-1450 on this 15th day of June, 2006.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

By:


Jason J. Derry, Ph.D.
Reg No. 50,692



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

| | | |
|-----------------------------|-----------------------|------------------|
| U.S. APPLICATION NUMBER NO. | FIRST NAMED APPLICANT | ATTY. DOCKET NO. |
| 10/520,142 | Igor B Roninson | 99,216-KK6 |

INTERNATIONAL APPLICATION NO.

PCT/US03/20425

I.A. FILING DATE

PRIORITY DATE

06/27/2003

07/03/2002

20306

MCDONNELL BOEHLEN HULBERT & BERGHOFF LLP
 300 S. WACKER DRIVE
 32ND FLOOR
 CHICAGO, IL 60606

DOCKETED

FEB 22 2006

CONFIRMATION NO. 5577

371 FORMALITIES LETTER



OC00000018062429

Date Mailed: 02/16/2006

DUE DATE: 4-16-06

BY: [Signature]

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

FRANCINE YOUNG

Telephone: (703) 308-9140 EXT 215

PART 1 - ATTORNEY/APPLICANT COPY

| U.S. APPLICATION NUMBER NO. | INTERNATIONAL APPLICATION NO. | ATTY. DOCKET NO. |
|-----------------------------|-------------------------------|------------------|
| 10/520,142 | PCT/US03/20425 | 99,216-KK6 |

FORM PCT/DO/EO/922 (371 Formalities Notice)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,216-KK6)

| | | |
|--|---|-------------------------------|
| In application of: |) | |
| |) | |
| Roninson <i>et al.</i> |) | Before the Examiner: |
| |) | |
| Serial No. 10/520,142 |) | |
| |) | Group Art Unit: |
| International Filing Date: 27 June 2003 |) | |
| |) | |
| For: Reagents and Methods for |) | Confirmation No.: 5577 |
| Identifying and Modulating |) | |
| Expression of Tumor Senescence |) | |
| Genes |) | |

Mail Stop Missing Parts
Commissioner for Patents
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY MAILED FEBRUARY 16, 2006


Sir:

Responsive to the Notice to Comply mailed February 16, 2006, attached please find a paper and Computer Readable Format of the sequence listing for the above-referenced U.S. Patent Application. Also, please find a statement that the content of the sequence listing information recorded in computer readable form is identical to the written sequence listing and includes no new matter. If the Examiner has any questions, please contact the below-signed at (312) 913-0001.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: June 15, 2006

By:


Jason J. Derry, Ph.D.
Reg. No. 50,692